BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gatto F, Hofland LJ. The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 2011;18:R233-51. [PMID: 22135243 DOI: 10.1530/ERC-10-0334] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Syguła A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cieślik E, Zeman M, Chmielik E, Sczasny J, Jarzab B, Handkiewicz-Junak D. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 35503379 DOI: 10.1007/s00259-022-05792-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY. Clinical Biology of the Pituitary Adenoma. Endocr Rev 2022:bnac010. [PMID: 35395078 DOI: 10.1210/endrev/bnac010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R, Auriemma RS. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. Front Endocrinol 2022;12:791633. [DOI: 10.3389/fendo.2021.791633] [Reference Citation Analysis]
4 Kim J, Oh JH, Harlem H, Culler MD, Ku CR, Lee EJ. Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas. Endocrinol Metab (Seoul) 2020;35:177-87. [PMID: 32207278 DOI: 10.3803/EnM.2020.35.1.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Cantone MC, Dicitore A, Vitale G. Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms. J Clin Med 2021;10:501. [PMID: 33535394 DOI: 10.3390/jcm10030501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Cuny T, Graillon T, Defilles C, Datta R, Zhang S, Figarella-Branger D, Dufour H, Mougel G, Brue T, Landsman T, Halem HA, Culler MD, Barlier A, Saveanu A. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary 2021;24:351-8. [PMID: 33433890 DOI: 10.1007/s11102-020-01113-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Refardt J, Hofland J, Kwadwo A, Nicolas GP, Rottenburger C, Fani M, Wild D, Christ E. Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. Rev Endocr Metab Disord 2021;22:581-94. [PMID: 32495250 DOI: 10.1007/s11154-020-09552-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
8 Corica G, Ceraudo M, Campana C, Nista F, Cocchiara F, Boschetti M, Zona G, Criminelli D, Ferone D, Gatto F. Octreotide-Resistant Acromegaly: Challenges and Solutions. Ther Clin Risk Manag 2020;16:379-91. [PMID: 32440136 DOI: 10.2147/TCRM.S183360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
9 Granata V, Fusco R, Setola SV, Castelguidone ELD, Camera L, Tafuto S, Avallone A, Belli A, Incollingo P, Palaia R, Izzo F, Petrillo A. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge. Radiol Oncol. 2019;53:373-387. [PMID: 31652122 DOI: 10.2478/raon-2019-0040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gatto F, Barbieri F, Arvigo M, Thellung S, Amarù J, Albertelli M, Ferone D, Florio T. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. Int J Mol Sci 2019;20:E3940. [PMID: 31412614 DOI: 10.3390/ijms20163940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
11 Gatto F, Arvigo M, Amarù J, Campana C, Cocchiara F, Graziani G, Bruzzone E, Giusti M, Boschetti M, Ferone D. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 2019;22:89-99. [PMID: 30483918 DOI: 10.1007/s11102-018-0926-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
12 Appay R, Tabouret E, Touat M, Carpentier C, Colin C, Ducray F, Idbaih A, Mokhtari K, Uro-Coste E, Dehais C, Figarella-Branger D; POLA network. Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. Acta Neuropathol Commun 2018;6:89. [PMID: 30193580 DOI: 10.1186/s40478-018-0594-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
13 Even-Zohar N, Greenman Y. Management of NFAs: medical treatment. Pituitary 2018;21:168-75. [PMID: 29344905 DOI: 10.1007/s11102-018-0865-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
14 Cooper O, Greenman Y. Dopamine Agonists for Pituitary Adenomas. Front Endocrinol (Lausanne) 2018;9:469. [PMID: 30186234 DOI: 10.3389/fendo.2018.00469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
15 Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, Masugi Y, Thiaglingam A, Brooks N, Nishihara R, Bonnemarie M, Masuda A, Inamura K, Kim SA, Mima K, Sukawa Y, Dou R, Lin X, Christiani DC, Schmidlin F, Fuchs CS, Mahmood U, Ogino S, Kulke MH. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas 2016;45:1386-93. [PMID: 27622342 DOI: 10.1097/MPA.0000000000000700] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]
16 Yong M, Yu T, Tian S, Liu S, Xu J, Hu J, Hu L. DR2 blocker thioridazine: A promising drug for ovarian cancer therapy. Oncol Lett 2017;14:8171-7. [PMID: 29344260 DOI: 10.3892/ol.2017.7184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
17 Fazekas-Singer J, Berroterán-Infante N, Rami-Mark C, Dumanic M, Matz M, Willmann M, Andreae F, Singer J, Wadsak W, Mitterhauser M, Jensen-Jarolim E. Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. Oncotarget 2017;8:83128-41. [PMID: 29137329 DOI: 10.18632/oncotarget.20914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
18 Veenstra MJ, van Koetsveld PM, Dogan F, Farrell WE, Feelders RA, Lamberts SWJ, de Herder WW, Vitale G, Hofland LJ. Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget 2018;9:14791-802. [PMID: 29599907 DOI: 10.18632/oncotarget.9462] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
19 Li P, Gui S, Cao L, Gao H, Bai J, Li C, Zhang Y. Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats. Onco Targets Ther 2016;9:2057-68. [PMID: 27103832 DOI: 10.2147/OTT.S94057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Fabian E, Haas B, Kump P, Lipp R, Kornprat P, Lutfi A, Talakic E, Fuchsjäger M, Spindelboeck W, Lackner C, Zollner G, Krejs GJ. Clinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver. Wien Klin Wochenschr 2016;128:277-86. [PMID: 26919853 DOI: 10.1007/s00508-016-0965-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol 2015;172:1-23. [PMID: 25671228 DOI: 10.1111/bph.12906] [Cited by in Crossref: 250] [Cited by in F6Publishing: 215] [Article Influence: 35.7] [Reference Citation Analysis]
22 Kim KW, Krajewski KM, Nishino M, Jagannathan JP, Shinagare AB, Tirumani SH, Ramaiya NH. Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR Am J Roentgenol 2013;201:811-24. [PMID: 24059370 DOI: 10.2214/AJR.12.10240] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
23 Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, Corsaro A, Villa V, Nizzari M, Florio T. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept 2013;2013:926295. [PMID: 23476673 DOI: 10.1155/2013/926295] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
24 Ferone D. Italian Society of Endocrinology Career Award Lecture: from somatostatin to…somatomedin. J Endocrinol Invest 2012;35:869-74. [PMID: 22932163 DOI: 10.3275/8583] [Reference Citation Analysis]
25 Fisseler-Eckhoff A, Demes M. Neuroendocrine tumors of the lung. Cancers (Basel) 2012;4:777-98. [PMID: 24213466 DOI: 10.3390/cancers4030777] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
26 Somvanshi RK, Kumar U. Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors. Pharmaceuticals (Basel) 2012;5:417-46. [PMID: 24281555 DOI: 10.3390/ph5050417] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]